Study Detail


Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection "ILIAD 7 trial"

Status: Open

Type: Interventional

Funder: RevImmune

Sponsor: RevImmune

CI: not available

IRAS-Number: 283184

CPMS-ID: 45586

Approval Date: 06 April 2020


RevImmune's goal is to successfully trial CYT107 on COVID-19 patients as part of a global effort to treat the disease. They believe IL-7 (CYT107) can prevent patients who are in the hospital for COVID-19 from progressing to having to be treated in the ICU. A Phase II randomized clinical trial is in the process of regulatory submission, building upon the prior and ongoing clinical trials of CYT107.

Study URL:

Back to listing